ngenla
pfizer europe ma eeig - somatrogon - growth and development - hypofÝzy a hypotalamickÝch hormÓny a ich analÓgy - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.
oxbryta
pfizer europe ma eeig - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
litfulo
pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - imunosupresíva - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.
xeljanz
pfizer europe ma eeig - tofacitinib - artritída, reumatoidná artritída - imunosupresíva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 a 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.
dalacin c 150 mg
pfizer europe ma eeig, belgicko - klindamycín - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)
dalacin t 1 % dermálny roztok
pfizer europe ma eeig, belgicko - klindamycín - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)
dalacin t 1 % dermálna emulzia
pfizer europe ma eeig, belgicko - klindamycín - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)
diflucan 150 mg
pfizer europe ma eeig, belgicko - flukonazol - 26 - antimycotica (lokÁlne a celkovÉ)
diflucan 100 mg
pfizer europe ma eeig, belgicko - flukonazol - 26 - antimycotica (lokÁlne a celkovÉ)
diflucan 50 mg
pfizer europe ma eeig, belgicko - flukonazol - 26 - antimycotica (lokÁlne a celkovÉ)